Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1962 1
1964 1
1981 1
1982 1
1983 1
1984 2
1985 2
1986 3
1987 2
1988 4
1989 7
1990 5
1991 11
1992 8
1993 15
1994 18
1995 24
1996 23
1997 29
1998 15
1999 23
2000 23
2001 22
2002 31
2003 50
2004 62
2005 87
2006 127
2007 135
2008 129
2009 120
2010 147
2011 203
2012 297
2013 330
2014 444
2015 439
2016 467
2017 567
2018 647
2019 795
2020 862
2021 1041
2022 479
Text availability
Article attribute
Article type
Publication date

Search Results

6,882 results
Results by year
Filters applied: . Clear all
Page 1
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.
Liu SY, Bao H, Wang Q, Mao WM, Chen Y, Tong X, Xu ST, Wu L, Wei YC, Liu YY, Chen C, Cheng Y, Yin R, Yang F, Ren SX, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Dong S, Zhang XC, Su J, Yang JJ, Yang XN, Zhou Q, Wu X, Shao Y, Zhong WZ, Wu YL. Liu SY, et al. Among authors: shao y. Nat Commun. 2021 Nov 8;12(1):6450. doi: 10.1038/s41467-021-26806-7. Nat Commun. 2021. PMID: 34750392 Free PMC article. Clinical Trial.
Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes.
Chen X, Wang D, Liu J, Qiu J, Zhou J, Ying J, Shi Y, Wang Z, Lou H, Cui J, Zhang J, Liu Y, Zhao F, Pan L, Zhao J, Zhu D, Chen S, Li X, Li X, Zhu L, Shao Y, Shu Y. Chen X, et al. Among authors: shao y. J Immunother Cancer. 2021 Nov;9(11):e003214. doi: 10.1136/jitc-2021-003214. J Immunother Cancer. 2021. PMID: 34795005 Free PMC article.
EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma.
Durbin AD, Wang T, Wimalasena VK, Zimmerman MW, Li D, Dharia NV, Mariani L, Shendy NAM, Nance S, Patel AG, Shao Y, Mundada M, Maxham L, Park PMC, Sigua LH, Morita K, Conway AS, Robichaud AL, Perez-Atayde AR, Bikowitz MJ, Quinn TR, Wiest O, Easton J, Schönbrunn E, Bulyk ML, Abraham BJ, Stegmaier K, Look AT, Qi J. Durbin AD, et al. Among authors: shao y. Cancer Discov. 2022 Mar 1;12(3):730-751. doi: 10.1158/2159-8290.CD-21-0385. Cancer Discov. 2022. PMID: 34772733 Free PMC article.
Disruption of MeCP2-TCF20 complex underlies distinct neurodevelopmental disorders.
Zhou J, Hamdan H, Yalamanchili HK, Pang K, Pohodich AE, Lopez J, Shao Y, Oses-Prieto JA, Li L, Kim W, Durham MA, Bajikar SS, Palmer DJ, Ng P, Thompson ML, Bebin EM, Müller AJ, Kuechler A, Kampmeier A, Haack TB, Burlingame AL, Liu Z, Rasband MN, Zoghbi HY. Zhou J, et al. Among authors: shao y. Proc Natl Acad Sci U S A. 2022 Jan 25;119(4):e2119078119. doi: 10.1073/pnas.2119078119. Proc Natl Acad Sci U S A. 2022. PMID: 35074918
Recent advances in enzyme-enhanced immunosensors.
Shao Y, Zhou H, Wu Q, Xiong Y, Wang J, Ding Y. Shao Y, et al. Biotechnol Adv. 2021 Dec;53:107867. doi: 10.1016/j.biotechadv.2021.107867. Epub 2021 Nov 12. Biotechnol Adv. 2021. PMID: 34774928 Review.
First total synthesis of hoshinoamide A.
Zhou H, Rui Z, Yang Y, Xu S, Shao Y, Liu L. Zhou H, et al. Among authors: shao y. Beilstein J Org Chem. 2021 Dec 15;17:2924-2931. doi: 10.3762/bjoc.17.201. eCollection 2021. Beilstein J Org Chem. 2021. PMID: 34956412 Free PMC article.
6,882 results